Kailera Therapeutics Files S-1MEF for Additional Securities

Ticker: KLRA · Form: S-1MEF · Filed: Apr 16, 2026

Sentiment: neutral

Topics: securities-offering, registration, pharmaceuticals

TL;DR

Kailera Therapeutics just filed to sell more stock. 🚀

AI Summary

Kailera Therapeutics, Inc. filed an S-1MEF on April 16, 2026, to register additional securities under a prior Form S-1 registration. The filing indicates the company's intent to offer more shares, building upon a previous registration. The company is located at 180 Third Avenue, Waltham, MA.

Why It Matters

This filing suggests Kailera Therapeutics is preparing to raise additional capital by offering more shares, which could impact its existing shareholders and future funding strategies.

Risk Assessment

Risk Level: medium — As an S-1MEF filing, it indicates a potential offering of securities, which carries inherent market and company-specific risks.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of an S-1MEF filing?

An S-1MEF filing is used to register additional securities to an already effective registration statement filed on Form S-1, pursuant to Rule 462(b).

When was this S-1MEF filing accepted by the SEC?

The filing was accepted on 2026-04-16 at 18:58:14.

What is Kailera Therapeutics, Inc.'s CIK number?

Kailera Therapeutics, Inc.'s CIK number is 0002096997.

Where is Kailera Therapeutics, Inc. located?

Kailera Therapeutics, Inc.'s business and mailing address is 180 THIRD AVENUE 4TH FLOOR WALTHAM MA 02451.

What is the SIC code for Kailera Therapeutics, Inc.?

The SIC code for Kailera Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form S-1MEF (Form S-1MEF) was filed with the SEC on April 16, 2026 regarding Kailera Therapeutics, Inc. (KLRA).

View full filing on EDGAR

View on Read The Filing